(Q40521915)

English

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study

scientific article published on April 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

phase II clinical trial

0 references

gynecologic oncology

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Ginger J. Gardner

9

object named as

Ginger J Gardner

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Farr Nezhat

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Scott Wadler

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

John Mandeli

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Gary Goldberg

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Jamal Rahaman

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Carolyn Runowicz

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Anthony J Murgo

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

1 April 2004

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

93

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

144-148

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

A phase II evaluation of cisplatin and 5-fluorouracil in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Isolation and structure of bryostatin 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Enhancement of the antiproliferative effect ofcis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Effect of modulation of protein kinase C activity on cisplatin cytotoxicity in cisplatin-resistant and cisplatin-sensitive human osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin: UCN-01, a selective protein kinase C inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Role of protein kinases in antitumor drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Enhancement of sensitivity to platinum(II)-containing drugs by 12-O-tetradecanoyl-phorbol-13-acetate in a human ovarian carcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Chemosensitivity testing with cis-platinum(II) diamminedichloride. II. Preliminary experience in the treatment of carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

Antiproliferative effect of complexes of platinum (II) with plasmanyl-(N-acyl)-ethanolamine, an inhibitor of protein kinase C

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2003.12.021

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.YGYNO.2003.12.021

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40521915&oldid=2127852305"